


PHARMACEUTICAL 2017

SteadyMed Ltd. Rank 227 of 313





PHARMACEUTICAL 2017

SteadyMed Ltd. Rank 227 of 313

The relative strengths and weaknesses of SteadyMed Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SteadyMed Ltd. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 44% points. The greatest weakness of SteadyMed Ltd. is the variable Research and Development, reducing the Economic Capital Ratio by 201% points.

The company's Economic Capital Ratio, given in the ranking table, is -425%, being 8.6% points below the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	23,382
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,357
Liabilities, Non-Current	7,490
Other Assets	227
Other Compr. Net Income	0
Other Expenses	2,293
Other Liabilities	0
Other Net Income	1,901
Property and Equipment	4,549
Research and Development	20,902
Revenues	1,065
Selling, General and Administrative Expense	5,640

Output Variable	Value in 1000 USD
Assets	28,158
Liabilities	13,847
Expenses	28,835
Stockholders Equity	14,311
Net Income	-25,869
Comprehensive Net Income	-25,869
Economic Capital Ratio	-425%